MIV Therapeutics Inc.
MIV THERAPEUTICS FINISHES SUCCESSFUL ROADSHOW IN EUROPE AND PUBLISHES ANALYST’S STUDY
MIV Therapeutics Inc. / Research Update Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Frankfurt, 28th of August, 2008 – MIV Therapeutics, Inc. (OTC/BB: MIVI) (Frankfurt: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices has presented itself on a Roadshow in Zurich, Geneva, London, Stockholm and Frankfurt to a huge number of investors within group events and one-to-one meetings. All together about 200 institutional investors, asset managers and analysts enjoyed during the past two weeks the opportunity of seeing the inspiring presentation by Dr. Mark Landy, CEO and President of MIV Therapeutics who pointed out the potential of MIV. To introduce the story of MIV Therapeutics to a larger group of potential investors the enterprise presented yesterday within the scope of the participation in the SCC - Small Cap Conference of the Society of Investment Professionals in Germany (DVFA) the study of an experienced LifeScience analyst. Dr. Roger Becker has intensely analysed MIV Therapeutics during the last weeks and has ascertained a significant undervaluation. The complete study which explains the business model of MIV Therapeutics as well as introduces the relevant market and the competitors can be downloaded under http://www.financial.de/imgs/newsletter/fde/080828/ResearchMIVenglisch.pdf free of charge. Dr. Mark Landy, CEO and President of MIV Therapeutics has summarised his impressions of the past days as follows: 'I had the pleasure during the past two weeks to get to know a large number of investment pros. The profound knowledge of my dialog partners and the discussions about yield chances and risks of an investment with MIV has shown me that the way is worthwhile to Europe over and over again. Also, I am glad a highly qualified European analyst initiated a positive report on MIV Therapeutics.' About MIV Therapeutics MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the 'Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents,' under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com. Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. All statements that discuss expectations and projections with respect to future matters including, without limitation, statements relating to the safety and efficacy of the Company’s product and the ability of the Company’s product to rejuvenate the stent market are forward-looking statements. Such statements are indicated by words or phrases such as 'proposed,' 'expected,' 'believe,' 'will,' 'breakthrough,' 'significant,' 'indicated,' 'feel,' 'revolutionary,' 'should,' 'ideal,' 'extremely' and 'excited.' These statements are made under 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, market acceptance of the Company’s product, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated, and other factors identified in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's annual report on Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The Company expressly disclaims any obligation to update publicly or otherwise revise these statements, whether as a result of new information, future events or otherwise, except to the extent required by law. For Investor Inquiries: Anthony L. Huston Vice President, Business Development & Investor Relations MIV Therapeutics, Inc. +1 604 301-9545, x14 ahuston@mivtherapeutics.com investor@mivtherapeutics.com Kim Sutton Golodetz kgolodetz@lhai.com Lippert/Heilshorn & Associates, Inc. +1 212 838-3777 For Media Inquiries: Michele Fox / Cassie Wallace Schwartz Communications +1 781-684-0770 miv@schwartz-pr.com 28.08.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden